View in EDS

Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB

Saved in:
Bibliographic Details
Title: Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB
Authors: Tilman Todenhöfer, Moritz Maas, Miriam Ketz, Nils Kossack, Christiane Colling, Bryan Qvick, Arnulf Stenzl
Source: World J Urol
Publisher Information: Springer Science and Business Media LLC, 2021.
Publication Year: 2021
Subject Terms: Male, Photosensitizing Agents, Carcinoma, Aminolevulinic Acid, Cystoscopy, Health Care Costs, Cystectomy, Cystoscopy/methods [MeSH], Health Care Costs/statistics, Aged [MeSH], Retrospective health service research, Aminolevulinic Acid/analogs, Urothelial cancer, Urinary Bladder Neoplasms/epidemiology [MeSH], Cystectomy/economics [MeSH], Germany/epidemiology [MeSH], Hexaminolevulinate, Original Article, Urinary Bladder Neoplasms/surgery [MeSH], Cystectomy/methods [MeSH], Health Services Research [MeSH], Male [MeSH], Photodynamic diagnosis, Transurethral bladder resection, Photosensitizing Agents/pharmacology [MeSH], Carcinoma/surgery [MeSH], Neoplasm Recurrence, Local/diagnosis [MeSH], Carcinoma/epidemiology [MeSH], Female [MeSH], Insurance Claim Review [MeSH], Humans [MeSH], Aminolevulinic Acid/pharmacology [MeSH], Retrospective Studies [MeSH], Cystectomy/adverse effects [MeSH], Urinary Bladder Neoplasms/pathology [MeSH], Carcinoma/pathology [MeSH], German claims data, Carcinoma/diagnostic imaging [MeSH], Neoplasm Recurrence, Local/epidemiology [MeSH], Urinary Bladder Neoplasms/diagnostic imaging [MeSH], 3. Good health, Insurance Claim Review, 03 medical and health sciences, 0302 clinical medicine, Urinary Bladder Neoplasms, Germany, Humans, Female, Health Services Research, Neoplasm Recurrence, Local, Aged, Retrospective Studies
Description: Purpose Photodynamic diagnosis using hexaminolevulinate (HAL)—guided BL-TURB may reduce the recurrence risk in non-muscle invasive BCa compared to standard WL-TURB due to more sensitive tumor detection. The impact of the initial use of WL- vs. BL-TURB on follow-up costs was evaluated in this real-world data analysis. Methods Anonymous claims data of German statutory health insurances (GKV) from 2011 to 2016 were analyzed in a primary and adjusted study population. Selection criteria included five quarters before enrolment, one index quarter (InQ) of initial TURB and BCa diagnosis, either within two years for the primary analysis or within four years for the adjusted analysis, and a follow-up period (FU) of either eleven or three quarters, respectively. Results In the primary analysis (n = 2331), cystectomy was identified as an important cost driver masking potential differences between cohorts. Therefore, patients undergoing cystectomy (InQ + FU) were excluded from the adjusted study population of n = 4541 patients (WL: 79%; BL: 21%). Mean total costs of BL-TURB were initially comparable to WL-TURB (WL: EUR 4534 vs. BL: EUR 4543) and tended to be lower compared to WL-TURB in the first two quarters of FU. After one year (3rd FU quarter), costs equalized. Considering total FU, mean costs of BL-TURB were significantly lower compared to WL-TURB (WL: EUR 7073 vs BL: EUR 6431; p = 0.045). Conclusion This retrospective analysis of healthcare claims data highlights the comparability of costs between BL-TURB and WL-TURB.
Document Type: Article
Other literature type
Language: English
ISSN: 1433-8726
0724-4983
DOI: 10.1007/s00345-020-03587-0
Access URL: https://link.springer.com/content/pdf/10.1007/s00345-020-03587-0.pdf
https://pubmed.ncbi.nlm.nih.gov/33569642
https://www.ncbi.nlm.nih.gov/pubmed/33569642
https://link.springer.com/article/10.1007/s00345-020-03587-0
https://link.springer.com/content/pdf/10.1007/s00345-020-03587-0.pdf
https://www.scilit.net/article/0cc39783017d09ed0941b184d48c3582
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405483
https://pubmed.ncbi.nlm.nih.gov/33569642/
https://repository.publisso.de/resource/frl:6451119
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) .
Accession Number: edsair.doi.dedup.....2f7953666afc9ad20f57469e15c0e69d
Database: OpenAIRE
Description
Abstract:Purpose Photodynamic diagnosis using hexaminolevulinate (HAL)—guided BL-TURB may reduce the recurrence risk in non-muscle invasive BCa compared to standard WL-TURB due to more sensitive tumor detection. The impact of the initial use of WL- vs. BL-TURB on follow-up costs was evaluated in this real-world data analysis. Methods Anonymous claims data of German statutory health insurances (GKV) from 2011 to 2016 were analyzed in a primary and adjusted study population. Selection criteria included five quarters before enrolment, one index quarter (InQ) of initial TURB and BCa diagnosis, either within two years for the primary analysis or within four years for the adjusted analysis, and a follow-up period (FU) of either eleven or three quarters, respectively. Results In the primary analysis (n = 2331), cystectomy was identified as an important cost driver masking potential differences between cohorts. Therefore, patients undergoing cystectomy (InQ + FU) were excluded from the adjusted study population of n = 4541 patients (WL: 79%; BL: 21%). Mean total costs of BL-TURB were initially comparable to WL-TURB (WL: EUR 4534 vs. BL: EUR 4543) and tended to be lower compared to WL-TURB in the first two quarters of FU. After one year (3rd FU quarter), costs equalized. Considering total FU, mean costs of BL-TURB were significantly lower compared to WL-TURB (WL: EUR 7073 vs BL: EUR 6431; p = 0.045). Conclusion This retrospective analysis of healthcare claims data highlights the comparability of costs between BL-TURB and WL-TURB.
ISSN:14338726
07244983
DOI:10.1007/s00345-020-03587-0